Two Oncologics Face Tough ODAC Review: Problems Of Efficacy For Schering's PegIntron And Safety For GSK's Votrient
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oncologic Drugs Advisory Committee will meet Oct. 5 to evaluate the sNDA for PegIntron to treat melanoma and the NDA for Votrient to treat renal cell carcinoma.
You may also be interested in...
Despite FDA Reservations, ODAC Votes Yes On Schering's PegIntron And GSK's Votrient
The panel voted 6-4 to recommend approval of the sBLA for PegIntron (peginterferon alfa-2b) for melanoma, and unanimously for Glaxo's Votrient (pazopanib) for advanced renal cell carcinoma.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.